[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337382-105":59,"doc-detail-337382-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","current-trends-and-future-prospects-of-drug-repositioning-in-gastrointestinal-oncology","Current trends and future prospects of drug repositioning in gastrointestinal oncology","","Gastrointestinal cancers contribute substantially to cancer incidence and mortality worldwide, yet effective treatments with improved prognoses and fewer side effects remain urgently needed. The slow, costly development of new drugs and early-stage trial failures motivate drug repurposing as an alternative strategy. This review summarizes therapeutic strategies, key challenges, and the rationale for using existing approved drugs with known safety and pharmacology to target gastrointestinal malignancies. It surveys diverse repurposing methodologies and examples across colorectal, pancreatic, and liver cancer subtypes, aiming to guide future research and clinical trials.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/current-trends-and-future-prospects-of-drug-repositioning-in-gastrointestinal-oncology/337382/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/current-trends-and-future-prospects-of-drug-repositioning-in-gastrointestinal-oncology/337382.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is drug repurposing (DR) in gastrointestinal oncology?","Question",{"text":113,"@type":114},"Drug repurposing uses existing approved drugs for other diseases, leveraging established safety and pharmacological data to evaluate new uses in treating gastrointestinal cancers.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why are new drug development efforts challenging for GI cancer treatment?",{"text":118,"@type":114},"Developing new drugs is lengthy and expensive, often requiring clinical trials that can fail early in the process.",{"name":120,"@type":111,"acceptedAnswer":121},"Which gastrointestinal cancer types are covered in the review’s drug repurposing examples?",{"text":122,"@type":114},"Examples of repurposed drugs are discussed across colorectal, pancreatic, and liver cancer types.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},337382,1790322617,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","TYPE Review  \nPUBLISHED 04 January 2024  \nDOI 10.3389/fphar.2023.1329244  \nOPEN ACCESS  \nEDITED BY  \nOnur Bender,  \nAnkara University, Türkiye  \nREVIEWED BY  \nFerda Kaleagasioglu, University of Istinye, Türkiye Purnima Singh,  \nUniversity of Tennessee Health Science Center (UTHSC), United States  \nSergio Alberto Bernal Chávez, Universidad de las Américas Puebla, Mexico  \n*CORRESPONDENCE  \nAndrea Riccio,  \n [andrea.riccio@unicampania.it](andrea.riccio@unicampania.it)[ ](andrea.riccio@unicampania.it)Mehdi Totonchi,  \n [m.totonchi@royaninstitute.org](m.totonchi@royaninstitute.org)  \nRECEIVED 28 October 2023  \nACCEPTED 11 December 2023  \nPUBLISHED 04 January 2024  \nCITATION  \nFatemi N, Karimpour M, Bahrami H, Zali MR, Chaleshi V, Riccio A, Nazemalhosseini-Mojarad E and Totonchi M (2024), Current trends and future prospects of drug repositioning in gastrointestinal oncology.  \nFront. Pharmacol. 14:1329244 .  \ndoi: 10.3389/fphar.2023.1329244  \nCOPYRIGHT  \n© 2024 Fatemi, Karimpour, Bahrami, Zali, Chaleshi, Riccio, NazemalhosseiniMojarad and Totonchi. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nCurrent trends and future prospects of drug repositioning in gastrointestinal oncology  \nNayeralsadat Fatemi 1, Mina Karimpour 2, Hoda Bahrami 2, Mohammad Reza Zali 3, Vahid Chaleshi 1, Andrea Riccio 4,5*, Ehsan Nazemalhosseini-Mojarad 3 and Mehdi Totonchi 1,4,6*  \n1Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran, 2Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran, 3Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran, 4Department of Environmental, Biological and Pharmaceutical Sciences and Technologies (DiSTABiF), Università degli Studi della Campania “Luigi Vanvitelli”, Caserta, Italy, 5Institute of Genetics and Biophysics (IGB) “Adriano Buzzati-Traverso”, Consiglio Nazionale delle Ricerche (CNR), Naples, Italy, 6Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran  \nGastrointestinal (GI) cancers comprise a signiﬁcant number of cancer cases worldwide and contribute to a high percentage of cancer-related deaths. To improve survival rates of GI cancer patients, it is important to ﬁnd and implement more effective therapeutic strategies with better prognoses and fewer side effects. The development of new drugs can be a lengthy and expensive process, often involving clinical trials that may fail in the early stages. One strategy to address these challenges is drug repurposing (DR) . Drug repurposing is a developmental strategy that involves using existing drugs approved for other diseases and leveraging their safety and pharmacological data to explore their potential use in treating different diseases. In this paper, we outline the existing therapeutic strategies and challenges associated with GI cancers and explore DR as a promising alternative approach. We have presented an extensive review of different DR methodologies, research efforts and examples of repurposed drugs within various GI cancer types, such as colorectal, pancreatic and liver cancers. Our aim is to provide a comprehensive overview of employing the DR approach in GI cancers to inform future research endeavors and clinical trials in this ﬁeld.  \nKEYWORDS  \ngastrointestinal cancers","cbCaid6XD0NjgodM","https://ap.wps.com/l/cbCaid6XD0NjgodM","pdf",1856957,29,"English","# Introduction\n# Therapeutic strategies and challenges in GI cancers\n# Drug repurposing as a promising alternative\n# Repurposing methodologies and examples by GI cancer type","[{\"question\":\"What is drug repurposing (DR) in gastrointestinal oncology?\",\"answer\":\"Drug repurposing uses existing approved drugs for other diseases, leveraging established safety and pharmacological data to evaluate new uses in treating gastrointestinal cancers.\"},{\"question\":\"Why are new drug development efforts challenging for GI cancer treatment?\",\"answer\":\"Developing new drugs is lengthy and expensive, often requiring clinical trials that can fail early in the process.\"},{\"question\":\"Which gastrointestinal cancer types are covered in the review’s drug repurposing examples?\",\"answer\":\"Examples of repurposed drugs are discussed across colorectal, pancreatic, and liver cancer types.\"}]","Current trends and future prospects of drug repositioning in gastrointestinal oncology | PDF",1790018923,73,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f054ff356d53b7bb4dea18277948951b.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5e2af0b87d89dc8a223559e12b9f06d.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42f85623fcdcd8983d4c64086a7189d2.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/72a6c073f1f99b28366c64b7a2dbf4f9.webp",980,1385]